Yu B Jiang from 261 Hett Ave, Staten Island, NY 10306, age 48

Us Patents

Substituted Anilinic Piperidines As Mch Selective Antagonists
view source
US Patent:

6727264, Apr 27, 2004
Filed:

Jul 3, 2002
Appl. No.:

10/188434
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ
John Wetzel - Fairlawn NJ
John E. DeLeon - North Bergen NJ
Yu Jiang - Jersey City NJ
Chien-An Chen - Fresh Meadows NY
Kai Lu - Elmwood Park NJ
Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ
International Classification:

A61K 31445
US Classification:

514323, 514331, 546200, 546234
Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Substituted Anilinic Piperidines As Mch Selective Antagonists
view source
US Patent:

7067534, Jun 27, 2006
Filed:

Nov 21, 2003
Appl. No.:

10/719358
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John Wetzel - Fairlawn NJ, US
John E. DeLeon - North Bergen NJ, US
Yu Jiang - Jersey City NJ, US
Chien-An Chen - Flushing NY, US
Kai Lu - Lake Hiawatha NJ, US
Assignee:

H. Lundbeck A/S - Valby-Copenhagen
International Classification:

A61K 31/445
C07D 401/06
US Classification:

514323, 514331, 546201, 546234
Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Substituted Alkyl Amido Piperidines
view source
US Patent:

7105544, Sep 12, 2006
Filed:

Jan 14, 2003
Appl. No.:

10/345063
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John M. Wetzel - Fair Lawn NJ, US
Chien-An Chen - Flushing NY, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ
International Classification:

A61K 31/445
C07D 211/26
US Classification:

514331, 514318, 546200, 546233, 546234
Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

Substituted Alkyl Amido Piperidines
view source
US Patent:

7199135, Apr 3, 2007
Filed:

Jan 6, 2004
Appl. No.:

10/753057
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John M. Wetzel - Athens OH, US
Chien-An Chen - Fresh Meadows NY, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Elmwood Park NJ, US
Assignee:

H. Lundbeck A/S - Copenhagen-Valby
International Classification:

A61K 31/445
C07D 401/04
US Classification:

514318, 546193, 546194
Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

Arylthiobenzylpiperidine Derivatives
view source
US Patent:

7329656, Feb 12, 2008
Filed:

Sep 21, 2005
Appl. No.:

11/231601
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Yu Jiang - Jersey City NJ, US
Chien-An Chen - Flushing NY, US
Kai Lu - Lake Hiawatha NJ, US
Kim Andersen - Ridgewood NJ, US
Assignee:

H. Lundbeck A/S - Valby
International Classification:

A61K 31/4545
A61K 31/444
A61K 31/5377
C07D 211/04
C07D 401/04
C07D 413/14
US Classification:

5142315, 514326, 514318, 546193, 546194, 546207, 544124, 544129
Abstract:

This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

Spirocyclic Piperidines As Mch1 Antagonists And Uses Thereof
view source
US Patent:

7335665, Feb 26, 2008
Filed:

Jul 3, 2003
Appl. No.:

10/518939
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Chien-An Chen - Flushing NY, US
John E. De Leon - North Bergen NJ, US
John Wetzel - Fairlawn NJ, US
Kim Andersen - Ridgewood NJ, US
Assignee:

H - Lundbeck A/S - Valby
International Classification:

A61K 31/438
C07D 221/20
C07D 491/10
US Classification:

514278, 546 17
Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

Amino Substituted Aryloxybenzylpiperidine Derivatives
view source
US Patent:

7446204, Nov 4, 2008
Filed:

Sep 20, 2005
Appl. No.:

11/230849
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Chien-An Chen - Flushing NY, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Kim Andersen - Ridgewood NJ, US
Assignee:

H. Lundbeck A/S - Valby - Copenhagen
International Classification:

C07D 211/14
A61K 31/451
US Classification:

546247, 514315
Abstract:

This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

Secondary Amino Anilinic Piperidines As Mch1 Antagonists And Uses Thereof
view source
US Patent:

7473698, Jan 6, 2009
Filed:

Jul 3, 2003
Appl. No.:

10/518675
Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Chien-An Chen - Flushing NY, US
John E. De Leon - North Bergen NJ, US
John Wetzel - Fairlawn NJ, US
Assignee:

H. Lunbeck A/S - Valby - Copenhagen
International Classification:

A61K 31/4465
US Classification:

514331, 546234
Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

Resumes

Yu Hui Jiang

view source

Yu Jiang

view source

Industry:

Education Management

Yu Jiang

view source

Skills:

Leadership
Microsoft Office
Microsoft Word
Powerpoint
Research
Microsoft Excel
Social Media
Marketing
Public Speaking
Customer Service

Yu Jiang

view source

Yu Jiang

view source

Yu Jiang Brooklyn, NY

view source

Work:

New York University

Sep 2009 to 2000
Research Assistant Mitsubishi Electrical Research Laboratories
Cambridge, MA
Jun 2013 to Aug 2013
Summer Research Intern Feedback Control Design

Mar 2010 to Mar 2012
Teaching Assistant for the lab session of EE3064 The Chinese University of Hong Kong
Hong Kong, Hong Kong Island
Nov 2007 to Dec 2007
Research Assistant

Education:

Polytechnic School of Engineering of New York University
Brooklyn, NY
2009 to 2014
PhD in Control and Optimization South China Unversity of Technology
Guangzhou, CN
2006 to 2009
M.Sc. in control theory and control engineering Sun Yat-sen (Zhongshan) University
Guangzhou, CN
2002 to 2006
B.Sc. in Mathematics

Skills:

MATLAB/Simulink, Mathematical Modeling, Algorithm Development, Optimization, Control Systems Design

Yu Jiang

view source

Location:

United States

Process Development Engineer At Lam Research

view source

Position:

Process Development Engineer at Lam Research

Location:

San Jose, California

Industry:

Semiconductors

Work:

Lam Research since Jun 2012
Process Development Engineer
Novellus Systems Jun 2011 - Jun 2012
Process Development Engineer
Lawrence Berkeley National Laboratory Nov 2009 - Jun 2011
Chemist Postdoc Fellow
University of California, Santa Cruz Sep 2004 - Aug 2009
Graduate Student Researcher
Novellus Systems Jun 2008 - Sep 2008
Process Intern

Education:

University of California, Santa Cruz 2004 - 2009
Ph.D, Condensed Matter Physics University of Science and Technology of China 1999 - 2004
B.S., Physics

Skills:

Fortran
Spectroscopy
Solid State Physics
X-ray
English
Mandarin
Linux
Shell Scripting
Chinese
LaTeX
Thin Films
Materials Science

Interests:

new science and technology, reading history books and scientific novels, surfing on the internet, watching films, enjoy good food

Honor & Awards:

Selected Publications “A Study of the local distortions of the Perovskite system La1-xSrxCoO3 (0 ≤ x ≤ 0.35) using the Extended X-ray Absorption Fine Structure technique”, Y. Jiang, F. Bridges, N. Sundaram, D. P. Belanger, I. E. Anderson, J. F. Mitchell, H. Zheng, Phys. Rev. B 80, 144423 (2009). “Local Structure of La1-xSrxCoO3 Determined from EXAFS and Neutron Pair Distribution Function Studies”, N. Sundaram, Y. Jiang, I. E. Anderson, D. P. Belanger, C. H. Booth, F. Bridges, J. F. Mitchell, Th. Proffen, and H. Zheng, Phys. Rev. Lett. 102, 026401 (2009). “Synthesis, Structural, and Optical Properties of Stable ZnS:Cu,Cl Nanocrystals”, C. Corrado, Y. Jiang, F. Oba, M. Kozina, F. Bridges, and J. Z. Zhang, J. Phys. Chem. A. 13, 3830 (2009). “Relationship between macroscopic physical properties and local distortions of low-doping La1-xCaxMnO3: An EXAFS study”, Y. Jiang, F. Bridges, L. Downward, and J. J. Neumeier, Phys. Rev. B 76, 224428 (2007).